Inhibiting Hsp90 sensitizes MDR ovarian cancer cells to chemotherapy by impairing the AKT/GSK3β/β-catenin signaling pathway, highlighting Hsp90 as a potential therapeutic target [129]. The gene discussed is HSP90AA1; the disease is ovarian carcinoma.